-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
common -X- _ B-Patient
cold -X- _ I-Patient
, -X- _ O
the -X- _ O
most -X- _ O
prevalent -X- _ O
contagious -X- _ O
viral -X- _ O
disease -X- _ O
in -X- _ O
humans -X- _ O
still -X- _ O
lacks -X- _ O
a -X- _ O
safe -X- _ O
and -X- _ O
effective -X- _ O
antiviral -X- _ O
treatment. -X- _ O
Iota-Carrageenan -X- _ B-Intervention
is -X- _ O
broadly -X- _ O
active -X- _ O
against -X- _ O
respiratory -X- _ O
viruses -X- _ O
in-vitro -X- _ O
and -X- _ O
has -X- _ O
an -X- _ O
excellent -X- _ O
safety -X- _ O
profile. -X- _ O
This -X- _ O
study -X- _ O
investigated -X- _ O
the -X- _ O
efficacy -X- _ B-Outcome
and -X- _ I-Outcome
safety -X- _ I-Outcome
of -X- _ O
an -X- _ O
Iota-Carrageenan -X- _ B-Intervention
nasal -X- _ I-Intervention
spray -X- _ I-Intervention
in -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
common -X- _ I-Patient
cold -X- _ I-Patient
symptoms. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
In -X- _ O
a -X- _ O
randomized -X- _ O
, -X- _ O
double-blind -X- _ O
, -X- _ O
placebo-controlled -X- _ O
exploratory -X- _ O
trial -X- _ O
, -X- _ O
35 -X- _ B-Patient
human -X- _ I-Patient
subjects -X- _ I-Patient
suffering -X- _ I-Patient
from -X- _ I-Patient
early -X- _ I-Patient
symptoms -X- _ I-Patient
of -X- _ I-Patient
common -X- _ I-Patient
cold -X- _ I-Patient
received -X- _ B-Intervention
Iota-Carrageenan -X- _ I-Intervention
( -X- _ I-Intervention
0.12 -X- _ I-Intervention
% -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ O
a -X- _ O
saline -X- _ O
solution -X- _ O
three -X- _ O
times -X- _ O
daily -X- _ O
for -X- _ O
4 -X- _ O
days -X- _ O
, -X- _ O
compared -X- _ B-Comparison
to -X- _ I-Comparison
placebo. -X- _ I-Comparison
RESULTS -X- _ O
: -X- _ O
Administration -X- _ B-Outcome
of -X- _ I-Outcome
Iota-Carrageenan -X- _ I-Outcome
nasal -X- _ I-Outcome
spray -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
symptoms -X- _ I-Outcome
of -X- _ I-Outcome
common -X- _ I-Outcome
cold -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.046 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
in -X- _ I-Outcome
nasal -X- _ I-Outcome
lavages -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
= -X- _ I-Outcome
0.009 -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
early -X- _ I-Outcome
symptoms -X- _ I-Outcome
of -X- _ I-Outcome
common -X- _ I-Outcome
cold. -X- _ I-Outcome
Pro- -X- _ I-Outcome
inflammatory -X- _ I-Outcome
mediators -X- _ I-Outcome
FGF-2 -X- _ I-Outcome
, -X- _ I-Outcome
Fractalkine -X- _ I-Outcome
, -X- _ I-Outcome
GRO -X- _ I-Outcome
, -X- _ I-Outcome
G-CSF -X- _ I-Outcome
, -X- _ I-Outcome
IL-8 -X- _ I-Outcome
, -X- _ I-Outcome
IL-1α -X- _ I-Outcome
, -X- _ I-Outcome
IP-10 -X- _ I-Outcome
, -X- _ I-Outcome
IL-10 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
IFN-α2 -X- _ I-Outcome
were -X- _ I-Outcome
reduced -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
Iota-Carrageenan -X- _ I-Outcome
group. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Iota-Carrageenan -X- _ B-Intervention
nasal -X- _ I-Intervention
spray -X- _ I-Intervention
appears -X- _ O
to -X- _ O
be -X- _ O
a -X- _ O
promising -X- _ B-Outcome
treatment -X- _ I-Outcome
for -X- _ I-Outcome
safe -X- _ I-Outcome
and -X- _ I-Outcome
effective -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
early -X- _ I-Outcome
symptoms -X- _ I-Outcome
of -X- _ I-Outcome
common -X- _ I-Outcome
cold. -X- _ I-Outcome
Larger -X- _ O
trials -X- _ O
are -X- _ O
indicated -X- _ O
to -X- _ O
confirm -X- _ O
the -X- _ O
results -X- _ O
. -X- _ O

